ANI Pharmaceuticals
ANIP
#5021
Rank
ยฃ1.24 B
Marketcap
ยฃ55.43
Share price
-2.06%
Change (1 day)
16.99%
Change (1 year)

P/E ratio for ANI Pharmaceuticals (ANIP)

P/E ratio as of March 2026 (TTM): 43.4

According to ANI Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 43.3772. At the end of 2024 the company had a P/E ratio of -49.4.

P/E ratio history for ANI Pharmaceuticals from 2001 to 2025

PE ratio at the end of each year

Year P/E ratio Change
2024-49.4
2022-13.2-6.66%
2021-14.2-8.21%
2020-15.4-112.52%
2019123261.64%
201834.1
201533.752.9%
201422.0-766.96%
2013-3.30

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
Novartis
NVS
21.7-49.96%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
Pfizer
PFE
19.6-54.80%๐Ÿ‡บ๐Ÿ‡ธ USA
Cardinal Health
CAH
33.0-23.96%๐Ÿ‡บ๐Ÿ‡ธ USA
Jazz Pharmaceuticals
JAZZ
-30.4-170.05%๐Ÿ‡ฎ๐Ÿ‡ช Ireland
Evoke Pharma
EVOK
-4.37-110.06%๐Ÿ‡บ๐Ÿ‡ธ USA
Celldex Therapeutics
CLDX
-8.64-119.92%๐Ÿ‡บ๐Ÿ‡ธ USA
Teva Pharmaceutical Industries
TEVA
25.1-42.23%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel
Royalty Pharma
RPRX
25.6-40.95%๐Ÿ‡ฌ๐Ÿ‡ง UK
Lannett Company
LCI
-0.0271-100.06%๐Ÿ‡บ๐Ÿ‡ธ USA

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.